CSIMarket
 


Bristol Myers Squibb Co  (BMY)
Other Ticker:  
 
 

BMY's Capital Expenditures Growth by Quarter and Year

Bristol Myers Squibb Co's Capital Expenditures results by quarter and year




BMY Capital Expenditures (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 283.00 251.00 290.00
III Quarter September - 153.00 190.00 224.00
II Quarter June - 131.00 191.00 198.00
I Quarter March 173.00 186.00 204.00 239.00
FY   173.00 753.00 836.00 951.00



BMY Capital Expenditures first quarter 2021 Y/Y Growth Comment
Bristol Myers Squibb Co reported decrease in Capital Expenditures in the first quarter by -6.99% to $ 173.00 millions, from the same quarter in 2020.
The decrease in the first quarter Bristol Myers Squibb Co's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures decrease of -3.45%.

Looking into first quarter results within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Capital Expenditures growth. While Bristol Myers Squibb Co' s Capital Expenditures decline of -6.99% ranks overall at the positon no. 305 in the first quarter.




BMY Capital Expenditures ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 12.75 % -13.45 % 14.17 %
III Quarter September - -19.47 % -15.18 % -14.5 %
II Quarter June - -31.41 % -3.54 % -20.16 %
I Quarter March -6.99 % -8.82 % -14.64 % -17.87 %
FY   - -9.93 % -12.09 % -9.86 %

Financial Statements
Bristol Myers Squibb Co's first quarter 2021 Capital Expenditures $ 173.00 millions BMY's Income Statement
Bristol Myers Squibb Co's first quarter 2020 Capital Expenditures $ 186.00 millions Quarterly BMY's Income Statement
New: More BMY's historic Capital Expenditures Growth >>


BMY Capital Expenditures (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 84.97 % 32.11 % 29.46 %
III Quarter September - 16.79 % -0.52 % 13.13 %
II Quarter June - -29.57 % -6.37 % -17.15 %
I Quarter March -38.87 % -25.9 % -29.66 % -5.91 %
FY (Year on Year)   - -9.93 % -12.09 % -9.86 %




Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #41
Overall #305

Capital Expenditures Y/Y Growth Statistics
High Average Low
102.98 % -3.45 % -100 %
(Sep 30 2016)   (Dec 31 2011)
Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #41
Overall #305
Capital Expenditures Y/Y Growth Statistics
High Average Low
102.98 % -3.45 % -100 %
(Sep 30 2016)   (Dec 31 2011)

Capital Expenditures by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Bristol Myers Squibb Co's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
98.67 % 8.35 % -100 %
(June 30. 2011)  


BMY's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2021 Bristol Myers Squibb Co realized fall in Capital Expenditures from the previous quarter by -38.87% to $ 173.00 millions, from $ 283.00 millions achived in the previous quarter.

This is not important issue, as Capital Expenditures frequently tend to plunge in the I. Quarter.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Bristol Myers Squibb Co's Capital Expenditures growth quarter on quarter, overall rank is 884.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #139
Overall #884
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #139
Overall #884
Capital Expenditures Q/Q Growth Statistics
High Average Low
98.67 % 8.35 % -100 %
(June 30. 2011)  


BMY's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2021 Bristol Myers Squibb Co disclosed fall in Capital Expenditures from the forth quarter by -38.87% to $ 173.00 millions, from $ 283.00 millions achived a quarter before.

But that's not huge concern, as I. Quarter Capital Expenditures frequently tend to plunge in the I. Quarter.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Bristol Myers Squibb Co's Capital Expenditures growth quarter on quarter, overall rank is 884.


Bristol Myers Squibb Co's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative Capital Expenditures 12 Months Ending $ 740.00 $ 753.00 $ 721.00 $ 758.00 $ 818.00
Y / Y Capital Expenditures Growth (TTM) -9.54 % -9.93 % -17.6 % -16.61 % -10.7 %
Year on Year Capital Expenditures Growth Overall Ranking # 227 # 231 # 1693 # 1181 # 1814
Seqeuential Capital Expenditures Change (TTM) -1.73 % 4.44 % -4.88 % -7.33 % -2.15 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 254 # 887 # 1544 # 1014 # 1720




Cumulative Capital Expenditures growth Comment
Bristol Myers Squibb Co showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Dec 31 2020. If the fiscal year would end in Mar 31 2021, Bristol Myers Squibb Co's annual Capital Expenditures decline would be -9.54% year on year to $740 millions.

Within the Healthcare sector 27 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 227, from total ranking in previous quarter at 231.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1193.98 %
28.52 %
-22.37 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 28
Overall # 227

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
928.57 %
28.73 %
-39.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 34
S&P 500 # 254
Cumulative Capital Expenditures growth Comment
Bristol Myers Squibb Co showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Dec 31 2020. If the fiscal year would end in Mar 31 2021, Bristol Myers Squibb Co's annual Capital Expenditures drop would be -9.54% year on year to $740 millions.

Within the Healthcare sector 27 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 227, from total ranking in previous quarter at 231.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1193.98 %
28.52 %
-22.37 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 28
Overall # 227

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
928.57 %
28.73 %
-39.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 34
S&P 500 # 254




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
BMY's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for BMY's Competitors
Capital Expenditures Growth for Bristol Myers Squibb Co's Suppliers
Capital Expenditures Growth for BMY's Customers

You may also want to know
BMY's Annual Growth Rates BMY's Profitability Ratios BMY's Asset Turnover Ratio BMY's Dividend Growth
BMY's Roe BMY's Valuation Ratios BMY's Financial Strength Ratios BMY's Dividend Payout Ratio
BMY's Roa BMY's Inventory Turnover Ratio BMY's Growth Rates BMY's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2021
Baxter International Inc -0.58%$ -0.581 millions
Therapeuticsmd Inc -1.14%$ -1.135 millions
Teleflex Incorporated-2.07%$ -2.073 millions
Orthofix Medical Inc -3.30%$ -3.297 millions
Gilead Sciences Inc -3.51%$ -3.509 millions
Livanova Plc-4.39%$ -4.385 millions
Phibro Animal Health Corp-4.66%$ -4.660 millions
Deciphera Pharmaceuticals Inc -4.78%$ -4.783 millions
Amphastar Pharmaceuticals Inc -4.85%$ -4.846 millions
Bausch Health Companies Inc -5.56%$ -5.556 millions
Align Technology inc -5.76%$ -5.759 millions
Syneos Health Inc -5.87%$ -5.872 millions
Cytomx Therapeutics Inc -6.39%$ -6.387 millions
Davita Inc -6.47%$ -6.473 millions
Apollo Endosurgery inc -6.60%$ -6.604 millions
Bristol Myers Squibb Co-6.99%$ -6.989 millions
Resmed Inc -9.23%$ -9.234 millions
Bio rad Laboratories Inc -9.47%$ -9.467 millions
Laboratory Corporation Of America Holdings-10.51%$ -10.507 millions
X4 Pharmaceuticals Inc-10.63%$ -10.631 millions
Chemed Corporation-11.06%$ -11.057 millions
Siga Technologies Inc-11.46%$ -11.464 millions
Alnylam Pharmaceuticals Inc -12.43%$ -12.433 millions
Pra Health Sciences Inc -12.70%$ -12.703 millions
Intercept Pharmaceuticals inc -12.73%$ -12.731 millions
Nuvasive Inc-14.17%$ -14.167 millions
Biocryst Pharmaceuticals Inc-14.66%$ -14.655 millions
Endo International Plc-14.79%$ -14.793 millions
Acadia Healthcare Company Inc -15.26%$ -15.258 millions
Concert Pharmaceuticals Inc -17.86%$ -17.857 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PMT's Profile

Stock Price

PMT's Financials

Business Description

Fundamentals

Charts & Quotes

PMT's News

Suppliers

PMT's Competitors

Customers & Markets

Economic Indicators

PMT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071